scholarly journals Cross‐sectional human immunodeficiency virus incidence estimation accounting for heterogeneity across communities

Biometrics ◽  
2019 ◽  
Vol 75 (3) ◽  
pp. 1017-1028 ◽  
Author(s):  
Yuejia Xu ◽  
Oliver Laeyendecker ◽  
Rui Wang
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cross Sectional ◽  
Virus Incidence ◽  
Immunodeficiency Virus ◽  
Incidence Estimation

scholarly journals Efficient estimation of human immunodeficiency virus incidence rate using a pooled cross‐sectional cohort study design

2020 ◽  
Vol 39 (24) ◽  
pp. 3255-3271
Author(s):  
Kesaobaka Molebatsi ◽  
Lesego Gabaitiri ◽  
Lucky Mokgatlhe ◽  
Sikhulile Moyo ◽  
Simani Gaseitsiwe ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cohort Study ◽  
Incidence Rate ◽  
Study Design ◽  
Efficient Estimation ◽  
Cross Sectional ◽  
Virus Incidence ◽  
Immunodeficiency Virus ◽  
Cohort Study Design

scholarly journals SAT0078 SAFETY OF LOW DOSE METHOTREXATE (MTX) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 974.2-974
Author(s):  
A. Gunay ◽  
A. Davidson ◽  
I. Colmegna ◽  
D. Lacaille ◽  
H. Loewen ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Adverse Events ◽  
Low Dose ◽  
Opportunistic Infections ◽  
Case Reports ◽  
Cross Sectional Study ◽  
Study Quality ◽  
Sectional Study ◽  
Cross Sectional ◽  
Immunodeficiency Virus

Background:Increased awareness of the efficacy of MTX in rheumatic disease is leading to more MTX use in patients from HIV endemic areas. While HIV related immunosuppression may contribute to improvement of some rheumatic diseases, immune reconstitution from highly active antiretroviral therapy (HAART) may lead to exacerbation or presentation of autoimmune disorders for which MTX therapy may be warranted. Most management guidelines for rheumatic disease do not address MTX use in the context of HIV.Objectives:To systematically review the published literature on the safety of using MTX ≤30 mg per week in HIV.Methods:We searched CINAHL, Embase, Global, MEDLINE and World of Science databases (Jan 1990 to May 2018) for terms including ‘methotrexate’ and ‘human immunodeficiency virus’. We also searched citations from review articles. Titles, abstracts or full manuscripts were screened independently by 2 reviewers to identify studies reporting HIV in patients taking MTX. Study quality was assessed using the McGill Mixed Methods Appraisal Tool (MMAT). Data was extracted on MTX and HIV adverse events (MTX toxicity, HIV viral load, CD4 count). Descriptive summaries are presented for studies providing outcomes in patients taking MTX ≤30 mg per week.Results:After removing duplicates and studies not meeting criteria or not providing sufficient information, 42 of the 2714 identified reports were included (1 clinical trial, 2 cohort, 1 cross-sectional study, 38 case reports/case series). Most reports (81%) originated from USA or Europe. Study quality was generally good with most studies fulfilling 50-100% of MMAT criteria. The randomized controlled trial (USA) assessing MTX on atherosclerotic disease in HIV showed that adverse events were more common in MTX versus placebo (12.8% vs 5.6%, p non-inferiority <0.05) and included infection, transient CD4 and CD8 drop, pulmonary toxicity, and death (1 attributed to MTX/HIV, 1 unrelated). One cohort study (South Africa) reported 43 RA patients on MTX who acquired HIV. In this cohort, RA generally improved despite only 5 individuals continuing MTX. No data on MTX adverse event rates was reported. One cohort study (USA) reported 13 HIV patients with myositis. One received MTX (with other immunosuppression) without MTX adverse effects but died due to AIDS. A cross-sectional study (France) of 43 HIV pts with autoimmune disease reported one patient on MTX (and other immunosuppression) developed an adverse event (cytopenia) compared to 5/33 patients not on MTX (cytopenia). The 38 case reports/series described 54 individuals with HIV receiving MTX. Of these studies, 27 (describing 42 subjects) reported on MTX adverse events and 35 (describing 46 subjects) reported on HIV adverse events. MTX adverse events developed in 29 subjects (hematologic 13, renal/hepatic 1, opportunistic infections 10, other events 2). HIV adverse events were noted in 23 subjects (Kaposi’s sarcoma 4, CD4 decrease 16, HIV viral titer increase 4). Five deaths were reported (2 infection, 1 infection and wasting, 2 HIV related deaths). Most subjects also received corticosteroids or other immunosuppressants including biologics.Conclusion:There remains limited data on the safety of low dose MTX in HIV. Surveillance for HIV is warranted for individuals on MTX who are at risk for acquiring HIV. Caution and careful monitoring for MTX toxicity, opportunistic infections and HIV state is suggested if MTX is used in the setting of HIV particularly if combined with other immunosuppression.References:[1] Clin Infectious Disease 2019:68[2] J Rheumatology 2014:41[3] Arthritis and Rheumatism 2003:49[4] Medicine 2017:96Acknowledgments :Funding from International League Against RheumatismMcGill University Global Health Scholar AwardsDisclosure of Interests:Alize Gunay: None declared, Anna Davidson: None declared, Ines Colmegna: None declared, Diane Lacaille: None declared, Hal Loewen: None declared, Michele Meltzer: None declared, Yewondwossen Mengistu: None declared, Rosie Scuccimarri: None declared, Zenebe Yirsaw: None declared, Sasha Bernatsky: None declared, Carol Hitchon Grant/research support from: UCB Canada; Pfizer Canada

scholarly journals Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques

2006 ◽  
Vol 80 (2) ◽  
pp. 999-1014 ◽  
Author(s):  
W.M. Blay ◽  
S. Gnanakaran ◽  
B. Foley ◽  
N. A. Doria-Rose ◽  
B. T. Korber ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Disulfide Bonds ◽  
Neutralizing Antibodies ◽  
Outer Region ◽  
Synonymous Substitution ◽  
Cross Sectional Study ◽  
Macaca Nemestrina ◽  
Cross Sectional ◽  
Immunodeficiency Virus ◽  
And Shifts

ABSTRACT We have analyzed changes to proviral Env gp120 sequences and the development of neutralizing antibodies (NAbs) during 1 year of simian/human immunodeficiency virus SHIV-89.6P infection in 11 Macaca nemestrina macaques. Seven macaques had significant env divergence from that of the inoculum, and macaques with greater divergence had higher titers of homologous NAbs. Substitutions in sequons encoding potential N-linked glycosylation sites (PNGs) were among the first to be established, although overall the total number of sequons did not increase significantly. The majority (19 of 23) of PNGs present in the inoculum were conserved in the sequences from all macaques. Statistically significant variations in PNGs occurred in multiple macaques within constrained regions we term “hot spots,” resulting in the selection of sequences more similar to the B consensus. These included additions on V1, the N-terminal side of V4, and the outer region of C2. Complex mutational patterns resulted in convergent PNG shifts in V2 and V5. Charge changes in Env V1V2, resulting in a net acidic charge, and a proline addition in V5 occurred in several macaques. Molecular modeling of the 89.6P sequence showed that the conserved glycans lie on the silent face of Env and that many are proximal to disulfide bonds, while PNG additions and shifts are proximal to the CD4 binding site. Nonsynonymous-to-synonymous substitution ratios suggest that these changes result from selective pressure. This longitudinal and cross-sectional study of mutations in human immunodeficiency virus (HIV) env in the SHIV background provides evidence that there are more constraints on the configuration of the glycan shield than were previously appreciated.

Pengetahuan dan Sikap Wanita Pekerja Seks (WPS) dalam Upaya Penanggulangan HIV/AIDS dengan Persuasi Penggunaan Kondom di Eks Lokalisasi Gempol Porong Kabupaten Banyuwangi Tahun 2019

2021 ◽  
Vol 2 (1) ◽  
pp. 55-63
Author(s):  
Machria Rachman
Keyword(s):  
Human Immunodeficiency Virus ◽  
Acquired Immunodeficiency Syndrome ◽  
Chi Square ◽  
Cross Sectional ◽  
Immunodeficiency Virus ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Hiv Aids

HIV (Human Immunodeficiency Virus)  dan AIDS (Acquired Immunodeficiency Syndrome masih menjadi ancaman kesehatan masyarakat secara global. Prevalensi HIV/AIDS di Kabupaten Banyuwangi juga cukup tinggi yakni 4.557 kasus. Cara penularan HIV terbesar adalah melalui hubungan seksual (71 %). Sejumlah 18,23% orang dengan HIV/AIDS (ODHA) adalah wanita pekerja seks (WPS). Meskipun lokalisasi di Banyuwangi telah resmi ditutup pada tahun 2013, namun praktik prostitusi masih terselubung dijalankan. Hubungan seksual tanpa kondom menjadi mata rantai penyebaran HIV/AIDS di masyarakat. Tujuan penelitian ini adalah untuk mengetahui korelasi pengetahuan dan sikap WPS dengan persuasi penggunaan kondom di eks lokalisasi Gempol Porong Kabupaten Banyuwangi. Desain penelitian adalah analitik kuantitatif dengan menggunakan pendekatan cross sectional. Sampel penelitian yaitu WPS di Eks Lokalisasi Gempol Porong berjumlah 32 orang yang diambil dengan teknik Total sampling. Pengambilan data dengan metode angket dan dianalisis statistik menggunakan SPSS 20.0 version. Hasil penelitian menunjukkan bahwa WPS yang memiliki pengetahuan rendah dalam penanggulangan HIV/AIDS sebanyak 56,2 %, sikap negatif sebesar 53,1% dan sebanyak 59,4% tidak melakukan persuasi penggunaan kondom. Analisis uji chi-Square menunjukkan ada hubungan antara pengetahuan WPS dalam penanggulangan HIV/AIDS dengan persuasi penggunaan kondom (ρ = 0,002α), serta ada hubungan antara sikap WPS dalam upaya penanggulangan HIV/AIDS dengan persuasi penggunaan kondom (nilai ρ = 0,000α). Variabel yang berpengaruh terhadap penanggulangan HIV/AIDS dengan persuasi penggunaan kondom adalah sikap, dengan  probabilitas sikap negatif WPS sebesar 78%. Penelitian ini diharapkan dapat memberikan masukan pihak terkait guna peningkatan 100% penggunaan kondom sehingga dapat menekan angka pertumbuhan HIV/AIDS di Kabupaten Banyuwangi.

scholarly journals A High Prevalence Rate of a Positive Screen for Cognitive Impairment in Patients With Human Immunodeficiency Virus Attending an Irish Clinic

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Patricia H. McNamara ◽  
Robert Coen ◽  
Janice Redmond ◽  
Colin P. Doherty ◽  
Colm Bergin
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cognitive Impairment ◽  
Large Scale ◽  
Screening Program ◽  
Cross Sectional Study ◽  
Hiv Positive ◽  
Study Cohort ◽  
Cross Sectional ◽  
Positive Screen ◽  
Immunodeficiency Virus

Abstract Background Human immunodeficiency virus (HIV)-associated neurocognitive disorders occurs in 20%–50% of HIV-positive patients. We undertook this study to assess the prevalence of a positive screen for cognitive impairment in the clinic population at our institution and to demonstrate the feasibility of implementing a screening program in routine clinical encounters. Methods This was a cross-sectional study, and patients were recruited prospectively between December 2010 and February 2013. Inclusion criteria were as follows: patients were HIV positive, over the age of 18, capable of giving informed consent, and had sufficient ability to communicate in English. Patients were screened for cognitive impairment using the Brief Neurocognitive Screen. Results A total of 604 patients were recruited, and 51.5% had a positive screen for cognitive impairment. The majority of the study cohort were male (78.8%), mean age was 40.9 (standard deviation, 10.2) years, 70.9% were Irish, the most common mode of transmission was men who have sex with men (49.3%), 83% were on antiretroviral therapy, and 88.7% were virally suppressed. Logistic regression showed that the main factors predictive of a positive screen for cognitive impairment were the endorsement of cognitive symptoms (P = .024), being born in Africa (P &lt; .000001), the use of benzodiazepines (P = .00341), being unemployed (P = .008), and consumption of more than 40 units of alcohol weekly (P = .035). There was a positive screen for depression in 9.1% and a positive screen for anxiety in 24.5%. Conclusions The study highlights the necessity for a structured, prospective, large-scale screening program for cognitive impairment across countries with limited resources and demonstrates the feasibility of easily implementing this with minimal training.

Sign in / Sign up

Export Citation Format

Share Document